Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma

Kasahara,Norimitsu; Wakuda,Kazushige; Omori,Shota; Nakashima,Kazuhisa; Ono,Akira; Taira,Tetsuhiko; Kenmotsu,Hirotsugu; Naito,Tateaki; Murakami,Haruyasu; Mori,Keita; Watanabe,Reiko; Endo,Masahiro; Nakajima,Takashi; Yamada,Masanobu; Takahashi,Toshiaki

doi:10.3892/mco.2017.1198

Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma

Authors:
- Norimitsu Kasahara
- Kazushige Wakuda
- Shota Omori
- Kazuhisa Nakashima
- Akira Ono
- Tetsuhiko Taira
- Hirotsugu Kenmotsu
- Tateaki Naito
- Haruyasu Murakami
- Keita Mori
- Reiko Watanabe
- Masahiro Endo
- Takashi Nakajima
- Masanobu Yamada
- Toshiaki Takahashi
View Affiliations

Affiliations: Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Shizuoka 411‑8777, Japan, Clinical Trial Coordination Office, Shizuoka Cancer Center, Nagaizumi, Shizuoka 411‑8777, Japan, Division of Diagnostic Pathology, Shizuoka Cancer Center, Nagaizumi, Shizuoka 411‑8777, Japan, Division of Diagnostic Radiology, Shizuoka Cancer Center, Nagaizumi, Shizuoka 411‑8777, Japan, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371‑8511, Japan
Published online on: March 17, 2017 https://doi.org/10.3892/mco.2017.1198
Pages: 718-722

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is no standard chemotherapy for pulmonary large-cell neuroendocrine carcinoma (LCNEC) and this type of cancer is difficult to diagnose using biopsy specimens. At the Shizuoka Cancer Center, when small biopsy specimens are used, they are diagnosed as high‑grade non‑small‑cell neuroendocrine carcinoma (HNSCNEC) and the patients are treated according to the small-cell lung cancer (SCLC) guidelines. Amrubicin is an effective second‑line treatment for patients with SCLC, although it remains unclear whether amrubicin monotherapy is effective for patients with LCNEC or HNSCNEC. Between September, 2004 and December, 2013, 18 patients with advanced LCNEC or HNSCNEC received amrubicin monotherapy in the second-line setting. The efficacy and toxicity of this treatment were retrospectively assessed. A total of 6 patients had LCNEC and 12 patients had HNSCNEC. The patients included 13 men, and the median age was 66 years (range, 57-82 years). A total of 16 patients had an Eastern Cooperative Oncology Group performance status of 0 or 1. All the patients had received platinum‑based chemotherapy as first‑line treatment, and the median number of amrubicin cycles per patient was 4 (range, 1‑9). The overall response rate was 11.1%. The median progression‑free and overall survival were 4.0 and 9.1 months, respectively. Grade 3 or 4 neutropenia was observed in 44% of the patients, and grade 3 febrile neutropenia occurred in 17% of the patients. One patient developed pneumonia and succumbed to the disease. Non-hematological toxicities were generally mild and manageable. Therefore, the efficacy of amrubicin in the second-line setting for patients with LCNEC or HNSCNEC is limited. Development of new drugs and/or treatment strategies is warranted.

View Figures

View References

1	Arrigoni MG, Woolner LB and Bernatz PE: Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 64:413–421. 1972.PubMed/NCBI
2	Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H and Doppman J: Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 15:529–553. 1991. View Article : Google Scholar : PubMed/NCBI
3	Travis W, Colby T, Corrin B, Shimosato Y and Brambilla E: World health organization international histological classification of tumours: Histological typing of lung and pleural tumours. 3rd. Berlin: Springer; 1999
4	Travis W, Brambilla E, Muller-Hermelink H and Harris C: World health organization classification of tumoursPathology and genetics: Tumours of the lung, pleura, thymus and heart. Lyon: IARC; 2004, View Article : Google Scholar
5	Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, et al: International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
6	Watanabe R, Ito I, Kenmotsu H, Endo M, Yamamoto N, Ohde Y, Kondo H, Nakajima T and Kameya T: Large cell neuroendocrine carcinoma of the lung: Is it possible to diagnose from biopsy specimens? Jpn J Clin Oncol. 43:294–304. 2013. View Article : Google Scholar : PubMed/NCBI
7	Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, et al: Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 23:8774–8785. 2005. View Article : Google Scholar : PubMed/NCBI
8	Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H and Nagai K: Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: A multicenter phase II study. J Thorac Oncol. 8:980–984. 2013. View Article : Google Scholar : PubMed/NCBI
9	Shimada Y, Niho S, Ishii G, Hishida T, Yoshida J, Nishimura M, Yoh K, Goto K, Ohmatsu H, Ohe Y and Nagai K: Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. Lung Cancer. 75:368–373. 2012. View Article : Google Scholar : PubMed/NCBI
10	von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, et al: Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 32:4012–4019. 2014. View Article : Google Scholar : PubMed/NCBI
11	Katakami N, Yoshioka H, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, et al: Amrubicin (AMR) versus docetaxel (DTX) as second- or third-line treatment for non-small cell lung cancer (NSCLC): A randomized phase III trial. Ann Oncol. 25:(Suppl 4). iv426–iv470. 2014. View Article : Google Scholar
12	Yoshida H, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K and Tamura T: Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol. 41:897–901. 2011. View Article : Google Scholar : PubMed/NCBI
13	Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, et al: Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic oncology research group study 0301. J Clin Oncol. 24:5448–5453. 2006. View Article : Google Scholar : PubMed/NCBI
14	Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, et al: Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 28:2598–2603. 2010. View Article : Google Scholar : PubMed/NCBI
15	Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, et al: Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan lung cancer study group trial 0402. J Clin Oncol. 26:5401–5406. 2008. View Article : Google Scholar : PubMed/NCBI
16	Murakami H, Yamamoto N, Shibata T, Takeda K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, et al: A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan clinical oncology group study (JCOG0901). Lung Cancer. 84:67–72. 2014. View Article : Google Scholar : PubMed/NCBI